Nativis

Seattle, United States Founded: 2002 • Age: 24 yrs
Developer of a therapeutic device for the treatment of cancer
Annual revenue - Latest available
Total funding $28.4M 9 rounds
Employees 13 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 5 Brand Intelligence

About Nativis

Nativis is a company based in Seattle (United States) founded in 2002. Nativis has raised $28.43 million across 9 funding rounds. The company has 13 employees as of December 31, 2010. Nativis operates in a competitive market with competitors including ChemoTech, IGEA, RanD and Papyrus Therapeutics, among others.

  • Headquarter Seattle, United States
  • Employees 13 as on 31 Dec, 2010
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $28.43 M (USD)

    in 9 rounds

  • Latest Funding Round
    $4.12 M (USD), Series B

    Nov 14, 2018

  • Investors
    Not available
  • Employee Count
    13

    as on Dec 31, 2010

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Nativis

Nativis has successfully raised a total of $28.43M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $4.12 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Nativis

Investments
Premium access

Investment portfolio details for Nativis

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Nativis

Premium access

Detailed financials for Nativis

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Nativis Comparisons

Nativis Primary company
Description
Developer of a therapeutic device for the treatment of cance...
Location
Seattle, United States
Founded Year
2002
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
13
As of 2010
Premium access

Peer comparison for Nativis

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Nativis

Nativis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChemoTech, IGEA, RanD and Papyrus Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of electroporation devices for the treatment of cancer
Locked Locked Locked
Orthopedic medical devices to promote reparative osteogenesis and joint protection
Locked Locked Locked
Medical devices for surgical oncology are developed using extracorporeal technologies.
Locked Locked Locked
Develops therapies for tumor suppression in various cancers through scientific research.
Premium access

Detailed competitors of Nativis

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Nativis

Premium access

Complete news archive for Nativis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nativis

Nativis was founded in 2002 and raised its 1st funding round 1 year after it was founded.

Nativis is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Nativis is a funded company, having raised a total of $28.43M across 9 funding rounds to date.

As of Dec 31, 2010, the latest employee count at Nativis is 13.

Nativis was founded in 2002 in Seattle, United States, and operates in the medical device sector focused on oncology and related conditions. A therapeutic device is developed that employs ultra-low radio frequency energy to target metabolic pathways at molecular and genetic levels. Treatments are provided for brain cancer, lung cancer, other cancers, inflammatory diseases, and chronic pain, with operations centered in the United States.

Nativis's top competitors include ChemoTech, RanD and IGEA.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available